In the AVAST-M trial, the VEGF inhibitor bevacizumab (Avastin, Genentech, Inc., San Francisco, CA, USA) was evaluated versus observation as an adjuvant therapy for primarily stage III melanomas. Here, VEGFA is linked to melanoma.